Skip to main content

Lotilaner - a novel formulation for cats provides systemic tick and flea control

Effective tick and flea control for pets is essential around the world for the health of companion animals, to limit zoonotic risk and to maintain a strong human-animal bond. Minimising pet exposure to ticks and preventing household infestations of fleas helps to prevent not only dermatitis and irritation but also vector-borne pathogen transmission to pets and people alike. A strong bond between owners and their pets has also been demonstrated to be beneficial to physical and psychological human health [1]. This bond is eroded by the presence of visible infestations and the feeling of revulsion they convey is reason enough for many owners to want to avoid infestation on their pets. Both the Companion Animal Parasite Council (capcvet.org) and the European Scientific Counsel Companion Animal Parasites (esccap.org) view tick and flea control as vital to maximise these benefits and reduce pathogen transmission. To achieve effective tick and flea control, highly efficacious adulticide products are required. Not only must these products eliminate ticks and fleas on the pet quickly, but they must also be easy to administer and affordable to the client, otherwise compliance will be lost. This is especially true in cats, where administration of treatment can be particularly challenging. Adverse behavioural and physiological reactions by cats to treatment administration can deter owners from treating them if other treatment modalities are then not available.

Just as the introduction of fipronil gave hope of safe flea control on dogs and cats, the development of modern tick and flea control products have brought increased flexibility and tick efficacy to the market. This is much needed at a time when flea challenge is increasing in most countries and climate change and increased movements of pets and people is fuelling increased distribution of ticks [2, 3]. The isoxazolines are highly efficacious novel ectoparasiticdes which form an important part of the arsenal that veterinary professionals have at their disposal to meet these challenges. Lotilaner, the novel isoxazline described in this article collection, provides a new tick and flea control option for cats which is not only highly efficacious, but also represents the first effective oral tick treatment product for cats.

This article collection contains a collection of papers evaluating the efficacy, safety and pharmaco-kinetics of lotilaner in cats. Elanco developed this drug as a highly efficacious and easy to administer solution to tick and flea infestations. The pharmacokinetic and safety studies described document that lotilaner is rapidly absorbed after oral administration and was not associated with any adverse side effects seen at rates above control groups, even at 5 times the maximum recommended dose [4]. The excellent oral safety profile of lotilaner is unique and especially important in cats, which are particularly susceptible to the toxic effects of certain ectoparasiticide drug classes such as pyrethroids and organophosphates [5].

The cat flea, Ctenocephalides felis, remains the predominant flea infesting cats worldwide and continues to infest homes, bringing misery to both pets and owners [2, 3]. Controlling infestations in as fast as possible time depends on a range of measures including effective treatment of the environment [3]. The most essential element in flea control, however, is treatment of all susceptible pets in a household frequently enough with an efficacious product to ensure flea egg production is halted. The experimental flea infestation studies in this article collection demonstrate that lotilaner begins killing fleas as as early as 8 hours post-administration and at 8 hours after subsequent weekly infestations of adult C. felis for at least 1 month [6]. The fast and sustained speed of kill of lotilaner is consistent with pharmacokinetic data in this article collection, showing that, following oral administration in fed cats, it is readily absorbed, with peak blood concentrations reached within 4 hours and a half-life of over 4 weeks [7]. Such rapid speed of kill not only results in breaking the flea life-cycle but also rapidly reduces flea biting which is beneficial in the reduction of flea allergic dermatitis (FAD). This was demonstrated in field trials, which confirmed an efficacy against fleas higher than 97% and that clinical signs of FAD were improved or eliminated [8].

The wide range of ticks infesting dogs capable of transmitting tick-borne disease, some of them zoonotic, has led to much attention from the media, veterinary professionals and industry. These ticks include Ixodes spp. capable of transmitting the agent of Lyme disease and tick-borne-encephaltitis, as well as Rhipicephalus sanguineus which not only transmits a wide range of pathogens, but can also infest homes and kennels [9]. What has received less attention, however, is that cats can and do also harbour these ticks. Cats are predominantly infested with Ixodes spp. [10, 11], but can also carry a wide range of other ticks such as Dermacentor spp. and Rhipicephalus spp. Although cats appear immunologically less susceptible to tick-borne disease and groom off many ticks before pathogen transmission can occur, there are tick-borne pathogens capable of causing potentially life-threatening disease in cats. These include Cytauxzoon felis in North America and Babesia felis in Africa [12, 13]. In addition, cats have the potential to bring ticks carrying pathogens of veterinary significance into closer proximity with domestic environments. “Babesia vulpes”, Borrelia spp. and Anaplasma phagocytophylum have all been found identified in Ixodes spp. found on cats [11]. The field studies in this article collection also found cats to be carrying R. sanguineus with the potential for cats to introduce this tick into homes where infestation might establish [14]. Effective tick treatments are therefore required to help mitigate these risks and the tick studies presented in this article collection demonstrate that lotilaner treatment readily eliminates infestation with Ixodes ricinus and ticks continued to be killed with high efficacy throughout the month following treatment [15]. Detailed studies with I. ricinus showed that lotilaner was effective against this tick within 12 h of treatment, reaching 100% efficacy within 24 h. It also sustained a rapid kill of newly infesting I. ricinus through 35 days [15]. The rapid onset of action and speed of kill are important to significantly reduce pathogen transmission. In an EU field study treating pet cats with lotilaner, R. sanguineus, Ixodes hexagonus and Dermacentor reticulatus were reduced by at least 96.4% as well as I. ricinus [14].

ESCCAP emphasises the importance of the availability of different methods of parasite preventive administration to maximise compliance, and in the field of cat tick prevention the lack of treatment options was a barrier for many years. Now a variety of treatment options are available but lotilaner represents the first efficacious oral option for the treatment of ticks and fleas on cats, addressing the needs of owners who would rather give their cat a tablet. This is only a useful alternative option for owners; however, if oral products are palatable and easy to administer. Studies in this article collection showed that lotilaner tablets were well accepted by cats [8]. Compliance remains vitally important in preventive medicine, for however efficacious and safe a product is, it will only be effective if administered correctly and consistently.

Pet ownership provides increased psychological and physical wellbeing and the human-animal bond is to be strongly encouraged. With pet ownership, however, comes the possibility of infestation with ticks and fleas and the health problems these may bring. The outdoor lifestyle and wildlife hunting activities that cats pursue place them in a position of introducing tick and flea vectors and the pathogens they carry directly into their own homes and other domestic situations. These risks can be mitigated, however, by vigilance and the application of effective parasiticides. Lotilaner is one such product, offering the novel option of both tick and flea treatment in an oral formulation. It provides safe and effective tick and flea control with rapid speed of kill and onset of action. In doing so, it provides veterinary professionals and cat owners another effective option in tick and flea control in the novel form of an oral formulation, in the ongoing battle to control ticks and fleas.

French translation of the Abstract is available in Additional file 1.

References

  1. Barker SB, Wolen AR. The benefits of human-companion animal interaction: a review. J Vet Med Educ. 2008;35:487–95.

    Article  PubMed  Google Scholar 

  2. Coles TB, Dryden MW. Insecticide/acaricide resistance in fleas and ticks infesting dogs and cats. Parasit Vectors. 2014;7:8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Dryden MW. Flea and tick control in the 21st century: challenges and opportunities. Vet Dermatol. 2009;20:435–40.

    Article  PubMed  Google Scholar 

  4. Kuntz AE, Kammanadiminti S. Safety of lotilaner flavoured chewable tablets (CredelioTM) after oral administration in cats. Parasit Vectors. 2018; In press; this collection

  5. Linnett PJ. Permethrin toxicosis in cats. Aust Vet J. 2008;86:32–5.

    Article  PubMed  Google Scholar 

  6. Cavalleri D, Murphy MG, Seewald W, Nanchen S. Laboratory evaluation of the efficacy and speed of kill of lotilaner (Credelio™) against Ctenocephalides felis on cats. Parasit Vectors. 2018 (In press; this collection).

  7. Toutain CE, Seewald W, Jung M. Pharmacokinetics of lotilaner following a single oral or intravenous administration in cats. Parasit Vectors. 2018 (In press; this collection).

  8. Cavalleri D, Murphy M, Seewald W, Nanchen S. A randomised, controlled field study to assess the efficacy and safety of lotilaner (Credelio™) in controlling fleas in client-owned cats in Europe. Parasit Vectors. 2018 (In press; this collection).

  9. Hansford KM, Pietzsch M, Cull M, Medlock JM. Brown dog tick infestation of a home in England. Vet Rec. 2015;176:129–30.

    Article  PubMed  Google Scholar 

  10. Claerebout E, Losson B, Cochez C, Casaert S, Dalemans A, De Cat A, et al. Ticks and associated pathogens collected from dogs and cats in Belgium. Parasit Vectors. 2013;6:183.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Davies S, Abdullah S, Helps C, Tasker S, Newbury H, Wall R. Prevalence of ticks and tick-borne pathogens: Babesia and Borrelia species in ticks infesting cats of Great Britain. Vet Parasitol. 2017;244:129–35.

    Article  PubMed  Google Scholar 

  12. Rizzi TE, Reichard MV, Cohn LA, Birkenheuer AJ, Taylor JD, Meinkoth JH. Prevalence of Cytauxzoon felis infection in healthy cats from enzootic areas in Arkansas, Missouri, and Oklahoma. Parasit Vectors. 2015;8:13.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Penzhorn BL, Schoeman T, Jacobson LS. Feline babesiosis in South Africa: a review. Ann N Y Acad Sci. 2004;1026:183–6.

    Article  PubMed  Google Scholar 

  14. Cavalleri D, Murphy M, Seewald W, Nanchen S. A randomised, controlled field study to assess the efficacy and safety of lotilaner (Credelio™) in controlling ticks in client-owned cats in Europe. Parasit Vectors. 2018 (In press; this collection).

  15. Cavalleri D, Murphy M, Seewald W, Drake J, Nanchen S. Laboratory evaluation of the efficacy and speed of kill of lotilaner (CredelioTM) against Ixodes ricinus ticks on cats. Parasit Vectors. 2018 (In press; this collection).

Download references

Funding

Publication of this paper has been sponsored by Elanco.

Availability of data and materials

Not applicable.

Author information

Authors and Affiliations

Authors

Contributions

The author is the sole contributor. The author read and approved the final manuscript.

Corresponding author

Correspondence to Ian Wright.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The author declares that he/she has no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional information

French version: Please see Additional file 1 (https://doi.org/10.1186/s13071-018-2970-x) for the French version of this Editorial article.

Additional file

Additional file 1:

French translation of the article. (PDF 58 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wright, I. Lotilaner - a novel formulation for cats provides systemic tick and flea control. Parasites Vectors 11, 407 (2018). https://doi.org/10.1186/s13071-018-2970-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13071-018-2970-x

Keywords